

Opticoat[®] 140

High efficient masking of scuffs on returnable glass containers in the filling plant

Opticoat[®] 140 is applied to scuffed container surfaces in the filling plant and improves the optical appearance of glass containers.

Opticoat[®] 140 offers the following benefits:

- High efficient masking of scuffs on beer and soft drinks bottles
- Improved bottle appearance
- Extend bottle life time based on visual appearance
- Positive environmental impact
- Restores the "new glass feel"
- Increases the marketing and brand values

All these advantages benefit the user of Opticoat[®] 140 exclusively.

PROPERTIES

Opticoat[®] 140 application dilution is an aqueous emulsion of esters.

- Active ingredients also used in the production of pharmaceuticals and cosmetics
- Superior spread characteristics on glass
- Resistant to condensation
- Coating is resistant against oxidation and therefore not subject to environmental influences
- No negative influence on appearance and adhesion of metallized or lacquered labels (must be confirmed by an application test)

Opticoat[®] 140 can be used in accordance with good manufacturing practices (GMP) in full compliance with the FDA regulations.

APPLICATION

Opticoat[®] 140 can be applied with different application means at different stages of the filling line.

In combination with the Arkema Opticoat[®] spray applicator, maximum performance can be achieved and the equipment is easily integrated into existing bottling lines.

Depending on the bottle surface conditions, bottle pre-treatment might be recommended.

APPLICATION CONCENTRATION

Opticoat[®] 140 concentrate will be diluted with water to 5 – 15% by weight, depending on the surface condition of the bottles and application technology.

By adding the concentrate to water, the aqueous dilution will be produced by self-emulsification. The ready-to-use dilution should be prepared with an Arkema recommended dosing unit.

CONSUMPTION

Depending on conditions of application and bottle size, the consumption is less than 80 mg of concentrate per bottle and trip.

PRODUCT DATA

Active ingredients	Mixture of esters
Appearance	Slightly yellow
Consistency	Low viscous
Specific gravity	0.86 g/cm ³

STORAGE

Opticoat[®] 140 should be stored in a closed container at room temperature (approx. 20°C, min. temperature 10°C), the shelf life is 2 years after date of production.

Once a container is opened, it is recommended to use material within 6 months.

Opticoat[®] 140 is sensitive to frost and should be transported and stored under frost-free conditions (Frost can lead to separation of product components. After instruction by Arkema the product can be remixed without loss of performance).

PACKAGING

50 kg	plastic drum
500 kg	plastic container

Please refer to the material safety data sheet for advice on toxicity and ecology.

To the best of our knowledge the information given here is correct, but without obligation.

Contact: glass.coating@arkema.com

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids (<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html>) Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations.

Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

glasscoating-arkema.com

ARKEMA
INNOVATIVE CHEMISTRY

Headquarters: Arkema France

420, rue d'Estienne d'Orves

92705 Colombes Cedex - France

Tel.: 33 (0)1 49 00 79 92

Fax: 33 (0)1 49 00 77 30

arkema.com